Speakers
Anderson Clark
Director, Translational In Vivo Pharmacology
EMD Serono Research & Development Institute
Day One
Thursday 13th December 2018
5:30 pm | Close of Conference Day One
8:20 am | Chair's Opening Remarks
Day Two
Thursday 13th December 2018
8:20 am | Chair's Opening Remarks
4:20 pm | Close of Conference
Haluk Yuzugullu
In Vivo Lead, Associate Principal Scientist, IMED
AstraZeneca
Day One
Thursday 13th December 2018
5:05 pm | Q&A - Modelling Cancer Drug Resistance
4:15 pm | PDX-Derived 3D Models to Study Drug Resistance and Novel Combinations
Anna Bunin
Associate Director - Immunology
Kleo Pharmaceuticals Inc.
Chen Zhao
Clinical Fellow
National Institutes of Health
Dan Powell
Director, Clinical Tumor Tissue Facility & Associate Professor
University of Pennsylvania
Day Two
Thursday 13th December 2018
9:45 am | Q&A Panel - Strategy – Selection – Characterization
8:55 am | Models to Understand the Mechanisms of Action of Cancer Biologic Therapies
Daniel Gioeli
Associate Professor
University of Virginia
Davy Ouyang
Executive Director
Crown Bioscience
Day One
Thursday 13th December 2018
10:10 am | Panel Discussion - The Changing Expectations of Model Requirements
8:55 am | Developing Human Target Knock-In Mouse Models for Immuno-Oncology Drug Discovery
Enrique Alvarez
Director - Preclinical Development
Kleo Pharmaceuticals Inc.
Esmaiel Jabbari
Professor
University of South Carolina
Workshop C
July 16, 2019
3:00 pm |
Considerations in Modeling the Microenvironment
Fangxian Sun
Lead Investigator - Research Pharmacology
Sanofi
Day Two
Thursday 13th December 2018
2:30 pm | Moderator Feedback Panel
Geeta Sharma
Scientific Fellow, Translational Research
Tesaro
Day Two
Thursday 13th December 2018
9:45 am | Q&A Panel - Strategy – Selection – Characterization
8:30 am | Preclinical Characterization of TSR-033, A Novel Therapeutic Antibody Targeting LAG-3
Hongmin Chen
Principal Scientist
Merck
Day Two
Thursday 13th December 2018
2:30 pm | Moderator Feedback Panel
Jenni Bernoulli
COO
Pharmatest Services
Alexander Adler
Scientist
Regeneron
Juan Delgado
Lead Data Scientist
Fuel3D
Kader Thiam
Vice President of Transgenic Technologies
genOway
Thiam received a Ph.D. for his work at the department of Cellular Immunology and in Infectious diseases at the Pasteur Institute, Lille (France). Then he was a fellow at The Pasteur Institute, Lille, Department of Peptide Chemistry. His work was focused on the regulation of the immune response by the use of recombinant viruses or synthetic agonist of cytokine, and on the intracellular delivery of lipopeptides modulating pharmacological targets. Thiam joined genOway, a company specialized in the generation of preclinical in vivo and in vitro models, in 1999. He first joined as Scientific Consultant and Head of the Immunology department. He then served the company as the director of Transgenic Technologies, driving the R&D programs aiming at developing new alternatives to overcome transgenesis limitations and new models for immune response monitoring and better predictability toward human situation. Today, he is the VP of Transgenic Technologies, overseeing feasibility, design, rationale and accuracy of the preclinical models developed by genOway.
Keiji Furuuchi
Associate Director & Head of Immunotherapy & Preclinical Development
Eisai
Kerry Whalen
Director - Discovery & Translational Biology
Tarveda Therapeutics
Lindsey Crowley
Scientist EMD
Serono
Day Two
Thursday 13th December 2018
2:30 pm | Moderator Feedback Panel
Maryland Franklin
Vice President – Scientific Development
MI Bioresearch
Mike Brehm
Professor
University of Massachusetts
Day One
Thursday 13th December 2018
10:10 am | Panel Discussion - The Changing Expectations of Model Requirements
9:20 am | Opportunities & Challenges in Utilizing Humanized Mice to Model Human T Cell Responses
Mithun Khattar
Scientist & Immuno- Oncology Lead
Takeda
Natalia Malkova
Lab Head/ Principal Research Investigator
Sanofi
Natalia Malkova is a principal research investigator in In vivo Pharmacology Group at Sanofi. She received her Ph.D. degree in molecular biology from Engelhardt Institute of Molecular Biology, Russia. She then continued her postdoctoral training in immunology at California Institute of Technology. Interests include cancer immunotherapy, tumor mouse models for preclinical and translational research, tumor microenvironment.
Day One
Thursday 13th December 2018
8:30 am | Local Immunotherapy with Cytokine mRNA Mixture Promotes Potent Anti-Tumor Immunity & Tumor Eradication Across Multiple Preclinical Tumor Models
Neil Michaud
Director, Translational Medicine
EpiZyme
Day One
Thursday 13th December 2018
5:05 pm | Q&A - Modelling Cancer Drug Resistance
4:40 pm | Translation of Preclinical Tumor Modeling of EZH2 Inhibition to Clinical Proof of Concept
Omid Ghasemi
Scientist I, Imaging
Takeda
Rhys Jones
Senior Director DMPK
Pfizer
Day Two
Thursday 13th December 2018
4:00 pm | Q&A Panel – Models Aiding Dose Translation and Understanding Drug Response
3:10 pm | Challenges & Opportunities in Understanding Drug Exposure at The Site Of Action and The Potential Implications of Transporter Mediated Efflux
Rick Huntress
Director of Commercial Business Development
The Jackson Laboratory
Day One
Thursday 13th December 2018
10:10 am | Panel Discussion - The Changing Expectations of Model Requirements
9:45 am | An overview of the JAX Human PDX Tumor Repository
Sarah Knutson
Director, Preclinical Biology
Twentyeight-Seven Therapeutics
Day Two
Thursday 13th December 2018
2:30 pm | Moderator Feedback Panel
Shanthi Ganesh
Associate Director
Dicerna Pharmaceuticals Corp.
Shiva Kazerounian
Associate Director, In Vivo Pharmacology Lead
BRG, LLC
Workshop A
July 16, 2019
11:30 am |
Challenges, Insights & Future Directions for Experimental Models in Cancer Immunotherapy
Shuxi Qiao
Senior Scientist Internal Medicine Research Unit
Pfizer Inc.
Silvia Goldoni
Investigator & Head of Oncology Lab
Novartis
Tseten Jamling
VP of Research and Development
Hera Biolabs
Yvonne Evrard
Operations Manager
Frederick National Laboratory for Cancer Research
Day Two
Thursday 13th December 2018